Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00761020 · ClinicalTrials.gov registry record · NA

Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection

A NA study of Malaria, sponsored by U.S. Army Medical Research and Development Command.

Completed
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT00761020: Completed NA study of Malaria, sponsored by U.S. Army Medical Research and Development Command.

NCT00761020 is a NA study of Malaria that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 31 participants, below the 257-participant average among 27 other Malaria trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00761020, a NA study of Malaria, has completed, sponsored by U.S. Army Medical Research and Development Command.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this trial is to study whether a certain blood test can reliably identify the presence of malaria in people who have been infected with, but who do not have symptoms of malaria.

Primary Outcome

The focus of the statistical analysis will be to estimate (with 95% confidence limits) the sensitivity of Pf assay in the mefloquine and control arms. Sensitivity will be calculated as the number of subjects in each cohort who develop at least a four-fold increase in antibody titer from baseline (measured positives) divided by the number infected (true positives). The binomial test will used to test the null hypothesis that the sensitivity in the mefloquine arm is at 30% α(= 0.05; one-sided). Th

Conditions Studied

Interventions

  • OTHER Control
  • DRUG Mefloquine

Study Locations (1)

Maryland

  • Walter Reed Army Institute of Research - Silver Spring

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2008-09
Est. Completion 2009-12
Phase NA

What the finished NCT00761020 record still lists

NCT00761020 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 257-participant average among 27 other Malaria trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Malaria appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.

NCT00761020 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00761020 about?

NCT00761020 is a clinical study titled "Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection". The main purpose of this trial is to study whether a certain blood test can reliably identify the presence of malaria in people who have been infected with, but who do not have symptoms of malaria.

What is the current status of trial NCT00761020?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2008-09. Estimated completion is 2009-12.

What conditions does trial NCT00761020 study?

This clinical trial studies the following conditions: Malaria.

What interventions are being tested in trial NCT00761020?

The interventions under investigation include: Control (OTHER), Mefloquine (DRUG).

Who is sponsoring clinical trial NCT00761020?

This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00761020 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malaria

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00761020's enrollment target sits among peer trials

31 21st of 27 higher than 7 of 27 other Malaria trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malaria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00761020, the US trial registry maintained by the National Library of Medicine. NCT00761020 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.